BioSig PURE EP System Featured in the Editorial of EP Lab Digest
January 14 2021 - 9:32AM
- Leading industry publication calls attention to ongoing
challenges in the electrophysiology lab
- PURE EP System is highlighted as a novel technological
solution
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced the PURE EP™ System was featured in the
January issue of EP Lab Digest.
The editorial, authored by the Editor-in-Chief Bradley P.
Knight, M.D., FACC, FHRS, highlights several challenges in
electrophysiology (EP), including loss of essential components of
the signal during the filtering process, inadequate signal-to-noise
ratio, and saturation of the signals during pacing and
defibrillation. According to Dr. Knight, the need for advancements
in signal recording are long overdue. Novel techniques to improve
EGM signal fidelity in EP labs are imperative for the efficacy of
ablation procedures.
Dr. Knight highlights how the PURE EP™ System addresses these
current limitations through its novel hardware architecture and its
proprietary signal processing software. He further elaborates on
the findings of the recent study titled “A novel cardiac signal
processing system for electrophysiology procedures: early insights
from the pure ep 2.0 study” recently presented during the European
Society of Cardiology Congress 2020. The independent, blinded
reviewers have rated 85% of the PURE EP™ signals as statistically
equivalent or better based on the evaluations from 34 pairs of
signals. In 35.5% of samples, the reviewers selected PURE EP™ data
because "more signal components were visible." Read the full
article here.
“We are committed to solving unmet clinical needs through
innovative technological solutions, and we are very pleased with
the growing industry recognition of our PURE EP™ System. We look
forward to expanding our physician collaborations in 2021 and
reporting on more clinical insights,” commented Kenneth L.
Londoner, Chairman, and CEO of BioSig Technologies, Inc.
This is the latest editorial in a series of publications
featuring BioSig’s PURE EP™ System in the industry-leading media
outlets. PURE EP™ System was recently highlighted in several
physician user’s interviews, including the December 2020 feature
interview with Rafaelle Corbisiero, M.D. and Pedram Kazemian, M.D.
of Deborah Heart and Lung Center and April 2020 interview with
Andrea Natale, M.D. of Texas Cardiac Arrhythmia Institute at St.
David’s Medical Center.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EPä System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording, and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024